Pathomechanism of MicroRNA-29 in Shoulder Stiffness

Chang Gung Medical Foundation

Status: Unknown

Conditions: Stiffness of Shoulder, Not Elsewhere Classified

Treatments: Biological: miR 29a

Study type: Interventional

Funder types: Other

Identifiers

NCT02534558

IRB 102-5462B

ChangGungMH (Other Identifier)

Details and patient eligibility

About

The team integrates experimental analyses of clinical and basic medicine and transgenic mice models. miR-29a acts a potent protective factor against excessive fibrosis in myofibroblasts of subacromial bursa tissue. Gain of miR-29a stabilizes tendon and synovial tissue homeostasis that alleviates tissue stiffness and maintains function.

Full description

Aims of first: The team will evaluate the associations among the mR-29a, miR-29b, miR-29c expression in subacromial bursa and subacromial fluid, incidence of shoulder stiffness, Constant scores, and VAS.

Aims of second: The team will isolate primary myofibroblast from subacromial bursa tissue as in vitro models and investigate the molecular events in the IL-1β modulation of miR-29a expression and the molecular mechanism underlying miR-29a inhibition of fibrotic matrix accumulation and apoptotic reactions in myofibroblast cultures.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged 18 to 80 years
• receiving surgery for open acromioplasty

Exclusion criteria

• shoulder disorders caused by traumatic fracture
• previous surgery
• osteoarthritis
• malignant disorders
• hepatic disorders
• renal disorders

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups

miR-29a precursor oligonucleotide

Experimental group

Description:

Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified

Treatment:

Biological: miR 29a

miR-29a antisense oligonucleotide

Experimental group

Description:

Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified

Treatment:

Biological: miR 29a